Humacyte Management

Management criteria checks 2/4

Humacyte's CEO is Laura Niklason, appointed in Jan 2004, has a tenure of 20.5 years. total yearly compensation is $2.63M, comprised of 23% salary and 77% bonuses, including company stock and options. directly owns 0.2% of the company’s shares, worth $1.27M. The average tenure of the management team and the board of directors is 2.9 years and 2.9 years respectively.

Key information

Laura Niklason

Chief executive officer

US$2.6m

Total compensation

CEO salary percentage	23.0%
CEO tenure	20.5yrs
CEO ownership	0.2%
Management average tenure	2.9yrs
Board average tenure	2.9yrs

Recent management updates

Shareholders Will Probably Not Have Any Issues With Humacyte, Inc.'s (NASDAQ:HUMA) CEO Compensation

Jun 05

Recent updates

Shareholders Will Probably Not Have Any Issues With Humacyte, Inc.'s (NASDAQ:HUMA) CEO Compensation

Jun 05

Humacyte: A Strong Opportunity In Wound Healing - A 'Buy' Before Price Gets Too High

May 14

CEO Compensation Analysis

How has Laura Niklason's remuneration changed compared to Humacyte's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	-US$106m
Dec 31 2023	US$3m	US$604k	-US$111m
Sep 30 2023	n/a	n/a	-US$89m
Jun 30 2023	n/a	n/a	-US$89m
Mar 31 2023	n/a	n/a	-US$29m
Dec 31 2022	US$2m	US$500k	-US$12m
Sep 30 2022	n/a	n/a	US$34m
Jun 30 2022	n/a	n/a	US$28m
Mar 31 2022	n/a	n/a	-US$26m
Dec 31 2021	US$11m	US$500k	-US$26m
Sep 30 2021	n/a	n/a	-US$85m
Jun 30 2021	n/a	n/a	-US$71m
Mar 31 2021	n/a	n/a	-US$69m
Dec 31 2020	US$619k	US$75k	-US$67m

Compensation vs Market: Laura's total compensation ($USD2.63M) is about average for companies of similar size in the US market ($USD3.38M).

Compensation vs Earnings: Laura's compensation has increased whilst the company is unprofitable.

CEO

Laura Niklason (61 yo)

20.5yrs

Tenure

US$2,625,702

Compensation

Dr. Laura E. Niklason, M.D., Ph D., serves as President and Chief Executive Officer at Humacyte, Inc. since November 2020. She founded Humacyte, Inc. in 2004 and served as its Chief Scientist from 2005 to...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Laura Niklason	Founder	20.5yrs	US$2.63m	0.20% $ 1.3m
Dale Sander	CFO, Chief Corporate Development Officer & Treasurer	3.7yrs	US$1.35m	0.019% $ 119.1k
Heather Prichard	Chief Operating Officer	5.2yrs	US$1.27m	0% $ 0
Juliana Blum	Co-Founder & Executive Advisor	no data	no data	no data
Sabrina Osborne	Chief People Officer	no data	no data	no data
William Scheessele	Chief Commercial Officer	2.9yrs	no data	0.013% $ 81.8k
Shamik Parikh	Chief Medical Officer	2.3yrs	US$1.53m	0% $ 0
Harold Alterson	Chief Quality Officer	1.9yrs	no data	no data
Yang Cao	Chief Regulatory Officer	1.8yrs	no data	no data

2.9yrs

Average Tenure

55yo

Average Age

Experienced Management: HUMA's management team is considered experienced (2.9 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Laura Niklason	Founder	20.5yrs	US$2.63m	0.20% $ 1.3m
Gordon Binder	Independent Director	2.9yrs	US$71.76k	0.18% $ 1.1m
Max Wallace	Independent Director	19.1yrs	US$76.76k	0.054% $ 340.2k
Brady Dougan	Director	19.5yrs	US$71.76k	0.43% $ 2.7m
Susan Windham-Bannister	Independent Director	2.9yrs	US$71.76k	0% $ 0
Todd Pope	Independent Director	no data	US$76.76k	0% $ 0
Rajiv Shukla	Director	2.9yrs	US$71.76k	1.52% $ 9.6m
Kathleen Sebelius	Independent Chairman of the Board	8.8yrs	US$96.76k	0.033% $ 207.6k
Michael Constantino	Independent Director	no data	US$79.26k	0.0078% $ 48.8k
Diane Seimetz	Independent Director	2.1yrs	US$71.76k	0% $ 0
Emery Brown	Independent Director	2.9yrs	US$71.76k	0% $ 0
C. Green	Independent Director	1.8yrs	US$71.76k	0% $ 0

2.9yrs

Average Tenure

65yo

Average Age

Experienced Board: HUMA's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.

Humacyte Management

Management criteria checks 2/4

Key information

Recent management updates

Independent Chairman of the Board exercised options to buy US$234k worth of stock.

Shareholders Will Probably Not Have Any Issues With Humacyte, Inc.'s (NASDAQ:HUMA) CEO Compensation

Chief Operating Officer recently sold US$502k worth of stock

Chief Operating Officer notifies of intention to sell stock

Independent Director recently bought US$668k worth of stock

Humacyte, Inc., Annual General Meeting, Jun 11, 2024

Recent updates

Humacyte, Inc.(NasdaqGS:HUMA) dropped from Russell Small Cap Comp Value Index

Humacyte, Inc. Presents Positive Preclinical Data for Its Biovascular Pancreas (Bvp™?) Program

Independent Chairman of the Board exercised options to buy US$234k worth of stock.

Shareholders Will Probably Not Have Any Issues With Humacyte, Inc.'s (NASDAQ:HUMA) CEO Compensation

Chief Operating Officer recently sold US$502k worth of stock

Chief Operating Officer notifies of intention to sell stock

Independent Director recently bought US$668k worth of stock

Humacyte: A Strong Opportunity In Wound Healing - A 'Buy' Before Price Gets Too High

Humacyte, Inc. to Report Q1, 2024 Results on May 10, 2024

Humacyte, Inc., Annual General Meeting, Jun 11, 2024

Consensus revenue estimates decrease by 12%, EPS upgraded

Price target increased by 7.1% to US$7.50

New major risk - Revenue and earnings growth

Humacyte, Inc. to Report Q4, 2023 Results on Mar 22, 2024

Humacyte, Inc. has completed a Follow-on Equity Offering in the amount of $40.2 million.

New minor risk - Shareholder dilution

Humacyte, Inc. has completed a Follow-on Equity Offering in the amount of $40.2 million.

Will Humacyte (NASDAQ:HUMA) Spend Its Cash Wisely?

Humacyte, Inc. Announces U.S. Food and Drug Administration Accepts and Grants Priority Review to Humacyte's Biologics License Application

New minor risk - Share price stability

Consensus revenue estimates decrease by 12%

Humacyte, Inc. Submits Biologics License Application to U.S. Food and Drug Administration Seeking Approval of Human Acellular Vessel (Hav) for the Treatment of Vascular Trauma

Humacyte, Inc. Announces Presentations of Positive Clinical Results of the Human Acellular Vessel™? (HAV™?) in the Treatment of Vascular Trauma

Humacyte, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Humacyte, Inc. Publishes Preclinical Results Showing Human Acellular Vessel™? Patency as Modified Blalock-Taussig-Thomas Shunt in Juvenile Primate Model

Founder exercised options to buy US$280k worth of stock.

Humacyte, Inc. Announces Positive Top Line Results from Phase 2/3 Trial of Human Acellular Vessel™? (HAV™?) in Treatment of Patients with Vascular Trauma

Humacyte, Inc. Announces the Presentation of Results from FDA Regulated, Investigator-Sponsored Clinical Study Conducted At the Mayo Clinic

Consensus revenue estimates fall by 33%

Humacyte, Inc. Presents Clinical Performance of Human Acellular Vessel (HAV) from Ukrainian Humanitarian Program

New major risk - Revenue size

First half 2023 earnings released: US$0.58 loss per share (vs US$0.17 profit in 1H 2022)

Humacyte, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Humacyte, Inc. Announces Publication of Biological Mechanism Explaining Low Rates of Infection Observed in Clinical Study of Human Acellular Vessel

Humacyte, Inc. Completes Enrollment in Phase 2/3 Trial of Human Acellular Vessel(Tm) (Hav(Tm)) for Vascular Trauma Repair

Chief Operating Officer exercised options to buy US$240k worth of stock.

First quarter 2023 earnings released: US$0.36 loss per share (vs US$0.19 loss in 1Q 2022)

Humacyte, Inc. to Report Q1, 2023 Results on May 12, 2023

Price target decreased by 24% to US$7.35

Consensus revenue estimates decrease by 45%, EPS upgraded

Price target decreased by 15% to US$9.46

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment deteriorates as stock falls 16%

Founder exercised options to buy US$321k worth of stock.

Investor sentiment improves as stock rises 15%

Humacyte, Inc. Announces Publication of 6-Year Outcomes of Phase 2 Study of Human-Tissue Engineered Blood Vessels for Peripheral Arterial Bypass, in Journal of Vascular Surgery – Vascular Science

Key Executive recently bought US$52k worth of stock

Investor sentiment deteriorated over the past week

Consensus EPS estimates fall by 13%

High number of new directors

Price target decreased to US$10.13

Consensus EPS estimates fall by 12%

Humacyte, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Humacyte: Intriguing Potential

Humacyte, Inc. Announces New Board Appointments

Investor sentiment improved over the past week

Independent Director recently bought US$193k worth of stock

Investor sentiment deteriorated over the past week

Consensus revenue estimates increase by 126%

Price target decreased to US$11.25

Second quarter 2022 earnings released: EPS: US$0.36 (vs US$0.76 loss in 2Q 2021)

Humacyte GAAP EPS of $0.35, revenue of $1.3M

Humacyte, Inc. to Report Q2, 2022 Results on Aug 12, 2022

High number of new directors

Humacyte, Inc. Announces Results Evaluating the Use of the Small-Diameter (3.5mm) Human Acellular Vessel for Coronary Artery Bypass Grafting in a Non-Human Primate Model

High number of new directors

Humacyte, Inc. Announces JAMA Surgery Publication Highlighting Potential of Human Acellular Vessel(TM) (HAV(TM)) to Expand Vascular Trauma Reconstruction and Bypass Treatment Options

Humacyte, Inc. Appoints Diane Seimetz to its Board of Directors

Humacyte, Inc. Presents New Immunogenicity Data on Human Acellular Vessels(Tm) (Havs(Tm))